-
公开(公告)号：WO2019034532A1
公开(公告)日：2019-02-21
申请号：PCT/EP2018/071649
申请日：2018-08-09
发明人： WEISKE, Jörg , STRESEMANN, Carlo , GRADL, Stefan, Nikolaus , RÖHN, Ulrike , CHRIST, Clara , STEUBER, Holger , HUSEMANN, Manfred , SCHMEES, Norbert , THEDE, Kai , SIEGEL, Stephan , TER LAAK, Antonius
IPC分类号： C07D243/12 , C07D243/24 , A61K31/55
摘要： The present invention covers 4-oxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-7- carboxamide compounds of general formula (I): in which R 1 , R 2a , R 2b , R 2c , R 3a , R 3b , R 4a , R 4b , R 5 and X are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer, as a sole agent or in combination with other active ingredients.
-
公开(公告)号：WO2018228920A1
公开(公告)日：2018-12-20
申请号：PCT/EP2018/065036
申请日：2018-06-07
申请人： BAYER PHARMA AKTIENGESELLSCHAFT , DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG , BAYER AKTIENGESELLSCHAFT
发明人： BUCHMANN, Bernd , SCHMEES, Norbert , MOWAT, Jeffrey Stuart , LEDER, Gabriele , PANKNIN, Olaf , CARRETERO, Rafael , AIGUABELLA FONT, Nuria , BRIEM, Hans , FRIBERG, Anders Roland , HUSEMANN, Manfred , BÖMER, Ulf , STÖCKIGT, Detlef , NEUHAUS, Roland , BERNDT, Sandra , PETERSEN, Kirstin , OFFRINGA, Rienk
IPC分类号： C07D471/04 , A61P35/00
摘要： The present invention relates to protein-inhibitory substituted pyrrolopyridine derivatives of formula (I) in which X, Y, R 1 , R 2 , R 3 and R 4 are as defined herein, to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, repectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients. The present invention further relates to the use, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of protein inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, in neurodegenerative disorders, in inflammatory disorders, in atherosclerotic disorders and in male fertility control.
-
3.发明申请
公开(公告)号：WO2018228923A1
公开(公告)日：2018-12-20
申请号：PCT/EP2018/065043
申请日：2018-06-07
申请人： BAYER PHARMA AKTIENGESELLSCHAFT , BAYER AKTIENGESELLSCHAFT , DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
发明人： SCHMEES, Norbert , BUCHMANN, Bernd , FRIBERG, Anders Roland , BRIEM, Hans , HUSEMANN, Manfred , BÖMER, Ulf , LEDER, Gabriele , CARRETERO, Rafael , STÖCKIGT, Detlef , OFFRINGA, Rienk
IPC分类号： C07D471/04 , A61K31/437 , A61P35/00
摘要： The present invention relates to protein-inhibitory substituted pyrrolopyridine derivatives of formula (I) in which X, Y, R 1 , R 2a , R 2b , R 3 and R 4 are as defined herein, to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, repectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients. The present invention further relates to the use, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of protein inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, in neurodegenerative disorders, in inflammatory disorders, in atherosclerotic disorders and in male fertility control.
-
4.发明申请SUBSTITUTED QUINAZOLINONE COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES 审中-公开取代的喹唑啉酮类化合物治疗增殖性疾病
公开(公告)号：WO2017162510A1
公开(公告)日：2017-09-28
申请号：PCT/EP2017/056229
申请日：2017-03-16
发明人： INCE, Stuart, James , HARTUNG, Ingo , HILLIG, Roman , FANGHÄNEL, Jörg , BRIEM, Hans , LIENAU, Philip , DENNER, Philip , NGUYEN, Duy , HUSEMANN, Manfred , BÖMER, Ulf
IPC分类号： C07D403/04 , C07D403/14 , C07D239/90 , C07D491/056 , A61K31/517 , A61P35/00 , A61P37/00
摘要： The present invention relates to substituted quinazolinone compounds of general formula (I) : in which R 1 , R 2 , R3, R 4 , R5, R6, R7, and R8 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.
摘要翻译： 本发明涉及通式（I）的取代的喹唑啉酮化合物：其中R 1，R 2，R 3，R
-
公开(公告)号：WO2018228925A1
公开(公告)日：2018-12-20
申请号：PCT/EP2018/065045
申请日：2018-06-07
发明人： SCHMEES, Norbert , BUCHMANN, Bernd , FRIBERG, Anders Roland , BRIEM, Hans , HUSEMANN, Manfred , BÖMER, Ulf , LEDER, Gabriele , CARRETERO, Rafael , STÖCKIGT, Detlef , OFFRINGA, Rienk
IPC分类号： C07D471/04 , A61K31/437 , A61P35/00
摘要： The present invention relates to protein-inhibitory substituted pyrrolopyridine derivatives of formula (I) in which X, Y, R 1 , R 2 , R 3 and R 4 are as defined herein, to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, repectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients. The present invention further relates to the use, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of protein inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, in neurodegenerative disorders, in inflammatory disorders, in atherosclerotic disorders and in male fertility control.
-
-
-
-
搜索结果
5 条记录 (耗时 0.022 秒)
